Navigation Links
Quality not quantity important for immune response to HIV

When it comes to an immune response against HIV, research funded by the Wellcome Trust in the UK and the National Institutes of Health in the US has found that bigger is not necessarily better, contrary to conventional medical wisdom. The research may have a profound impact on the development of a vaccine against the disease.

"Conventional medical wisdom tells us that the bigger the immune response, the more effective it will be in controlling HIV," says Professor Philip Goulder, a Wellcome Trust Senior Research Fellow in Clinical Science at the University of Oxford. "However, our study suggests that this might not be the case. While most of the immune responses generated against HIV appear to be ineffective, responses targeting one particular HIV protein can bring about control of the virus."

About 40 million people are thought to be living with HIV worldwide. The virus, which causes AIDS, is thought to kill 3 million people each year. Despite being first identified in 1981, a vaccine to prevent infection has so far proved elusive.

When HIV infects the body, it hides out in so-called "helper T-cells". T cells play an important role in the immune response generated by the body to fight infection. There are a number of different types of T cells, each playing a different role in this battle. Helper T-cells (HTCs) regulate the body's immune response and it is the loss of these cells that leads to the development of AIDS.

Another type of T cell, the cytotoxic T cell (CTC), recognises and attacks infected HTCs. It was previously thought that the bigger the CTC response, the more effective it would be. It is this dogma that has influenced development of HIV vaccines, with the vaccines attempting to stimulate a large response.

However, Professor Goulder and colleagues found that the type of CTC response is crucial and that some types of response may have a negative effect and could actually hinder the immune response. The res earch, a population-based study involving investigators at the University of Oxford in the UK, Partners AIDS Research Center at Massachusetts General Hospital in the US and the University of KwaZulu-Natal, South Africa, investigated the immune responses against HIV in nearly 580 HIV-infected people in KwaZulu-Natal. It is published online today in the journal Nature Medicine.

"Some of the CTCs attack so-called 'Gag' proteins within the HIV virus, whilst others attack proteins such as the 'Env' protein on its surface," explains Professor Goulder. "In our study group, it seems that the higher the response to the Gag proteins, the more effective the immune system was at fighting infection. However, for reasons that are unclear, the opposite was true for responses to the Env proteins, where a stronger response was associated with a higher viral load ?in other words, worse control of HIV."

Professor Goulder believes these findings may have implications for the development of a HIV vaccine.

"There seems to be clear evidence that 'Gag is good'," says Professor Goulder. "This means that rather than developing a vaccine with a spectrum of CTC responses, we may need to look at a more targeted vaccine."
'"/>

Source:Wellcome Trust


Related biology news :

1. UCSD Discovery Shows How Embryonic Stem Cells Perform Quality Control Inspections
2. Sleep quantity affects morning testosterone levels in older men
3. Nature provides inspiration for important new adhesive
4. Newly discovered protein an important tool for sleeping sickness research
5. Modified collagen could yield important medical applications
6. Understanding biases in epidemic models important when making public health predictions
7. Bugs expose underground carbon traffic system 10 times more important than fossil fuel burning
8. Bacteria that cause tooth decay able to survive without important biochemical pathway
9. Scientists a step closer to protecting worlds most important crop
10. Zinc plays important role in brain circuitry
11. Most important actors in the growth process of neurons identified

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... Who risk to be deprived of its ... report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG ... Fingerprint sensors using capacitive technology represent a fast growing ... forecasts an increase of 360% of the number of ... fingerprint sensor market between 2014 and 2017 (source : ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScanĀ® technology provides the fastest and most ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... MOSCOW and ROCKVILLE, Md. ... portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... of SQ109 added to the standard drug therapy regimen ... a new small molecule drug discovered by scientists at ... US National Institutes of Health. A ...
(Date:3/24/2017)... March 24, 2017   Sienna Biopharmaceuticals, Inc. , ... today announced that Richard Peterson will join ... Peterson, who brings more than two decades ... , who is retiring at the end of April ... capacity. Peterson joins Sienna from Novan, Inc., where he ...
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Global Markets" report to their offering. ... The Global Market ... Billion in 2016 at a CAGR of 8.9%, ... and non-energetic bioproducts into seven major product segments: bio-derived chemicals, ...
(Date:3/23/2017)... Calif., March 23, 2017  BioPharmX Corporation (NYSE ... for the dermatology market, today reported financial results ... 2017, and will provide an update on the ... year. "We are pleased to report ... for BioPharmX," said President Anja Krammer. "We achieved ...
Breaking Biology Technology: